Skip to main content
Steven Kornblau, MD, Oncology, Houston, TX, University of Texas M.D. Anderson Cancer Center

StevenM.KornblauMD

Oncology Houston, TX

Hematologic Oncology

Professor

Dr. Kornblau is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Kornblau's full profile

Already have an account?

Education & Training

  • Royal Free  Hospital,
    Royal Free Hospital,MD, Benign hematology, 1991 - 1991
  • University of Texas Health Science Center at Houston/M D Anderson Cancer Center
    University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
  • Baylor College of Medicine
    Baylor College of MedicineResidency, Internal Medicine, 1985 - 1988
  • University of Texas Medical Branch School of Medicine
    University of Texas Medical Branch School of MedicineClass of 1985

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • GA State Medical License
    GA State Medical License 2023 - 2026
  • WA State Medical License
    WA State Medical License 2023 - 2026
  • TX State Medical License
    TX State Medical License 1986 - 2025
  • TN State Medical License
    TN State Medical License 2023 - 2025
  • AZ State Medical License
    AZ State Medical License 2023 - 2025
  • OK State Medical License
    OK State Medical License 2023 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia Delineates Lineage Associated Molecular Subtypes  
    Koichi Takahashi, Marina Konopleva, Steven Kornblau, Hagop Kantarjian, Nitin Jain, Elias Jabbour, Courtney D DiNardo, Michael Andreeff, Nature
  • Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia Delineates Lineage Associated Molecular Subtypes  
    Koichi Takahashi, Nitin Jain, Courtney D. DiNardo, Steven Kornblau, Carlos Bueso-Ramos, Marina Konopleva, Hagop Kantarjian, Nature
  • Genomic Analyses Identify Recurrent MEF2D Fusions in Acute Lymphoblastic Leukaemia  
    Michael Borowitz, Hagop M Kantarjian, Cheryl L Willman, Stephen P Hunger, Selina M Luger, Clara D Bloomfield, Brent Wood, Jerald P Radich, Marina Konopleva, Stephen J ..., Nature

Abstracts/Posters

  • Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
    Steven M. Kornblau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic...
    Steven M. Kornblau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • The Mitochondrial Protease, Neurolysin (NLN), Regulates Respiratory Chain Complex and Supercomplex Formation and Is Necessary for AML Viability
    Steven M. Kornblau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Mechanisms Underlying Superior Efficacy of Co-Targeting BET Proteins and Anti-Apoptotic BCL2 or MCL1 Protein Against AML Blast Progenitor Cells 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromoso... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Authored Content

  • A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (Pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)October 2017

Press Mentions

  • Myelodysplastic Syndrome Survivor: A Stem Cell Transplant Put Me in Remission
    Myelodysplastic Syndrome Survivor: A Stem Cell Transplant Put Me in RemissionSeptember 3rd, 2019
  • New TMC Program Will Streamline Clinical Trials
    New TMC Program Will Streamline Clinical TrialsJune 3rd, 2019

Grant Support

  • Core B - Myeloma Tissue CoreNational Cancer Institute2010–2011
  • CML Cell BankNational Cancer Institute2010–2011
  • Pathology And Tissue CoreNational Cancer Institute2008–2011
  • Sample Distribution, Processing And Culture CoreNational Cancer Institute2007–2011
  • High Throughput Transcriptomics And ProteomicsNational Cancer Institute2007–2011
  • Sample Distribution, Processing, Banking And DatabaseNational Cancer Institute2005–2009
  • Core--Sample Distribution, Processing And CultureNational Cancer Institute2001–2002
  • Suicidal Lymphocytes For Induction Of Gvl--CmlNational Cancer Institute1998–2002
  • Core--Cell Collection, Fractionation, Growth, And Transplantation LaboratoryNational Cancer Institute1996–2001

Professional Memberships

Hospital Affiliations